Pixium Vision SA announces the geographical expansion of the PRIMAvera European pivotal trial in atrophic dry age-related macular degeneration (AMD) with the opening of the first clinical site in the UK at the Moorfields Eye Hospital in London. The Moorfields Eye Hospital in London, the premiere ophthalmology center in the UK, can now recruit patients into the PRIMAvera study, which aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe. The study was initiated in Fourth Quarter 2020 in France and the first patient was implanted in March 2021. The PRIMAvera study is planned to expand to additional clinical sites in Germany, Spain, the Netherlands and Italy over the course of second half of 2021. The PRIMAvera study design is based on the positive data generated in a French feasibility study, showing the ability of patients with dry AMD to potentially improve in visual acuity with the Prima System. Patients had a meaningful improvement in vision, gaining on average a logMAR of 0.5 (corresponding to 5 lines of improvement). A total of 38 patients will be enrolled in PRIMAvera, an open label, baseline-controlled, nonrandomized, multi-center, prospective, single-arm confirmatory trial. The primary efficacy endpoint is the proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more from baseline to 12 month and the primary safety endpoint is the number and severity of device and procedure related serious adverse events at 12 months follow-up. The study will include three years of follow-up, with assessment of the primary endpoints at 12 months after implantation.